Want to see XTLB full AI Analyst Report?
Total Valuation
XTL Biopharmaceuticals Sponsored ADR has a market cap or net worth of $6.00M. The enterprise value is $5.24M.
Market Cap$6.00M
Enterprise Value$5.24M
Share Statistics
XTL Biopharmaceuticals Sponsored ADR has 2,365,608 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding2,365,608
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
XTL Biopharmaceuticals Sponsored ADR’s return on equity (ROE) is 27.44 and return on invested capital (ROIC) is -11253.33%.
Return on Equity (ROE)27.44
Return on Assets (ROA)-41.98
Return on Invested Capital (ROIC)-11253.33%
Return on Capital Employed (ROCE)6.65
Revenue Per Employee0.00
Profits Per Employee-696.90K
Employee Count10
Asset Turnover―
Inventory Turnover―
Valuation Ratios
The current PE Ratio of XTL Biopharmaceuticals Sponsored ADR is ―. XTL Biopharmaceuticals Sponsored ADR’s PEG ratio is 0.00.
PE Ratio―
PS Ratio0.00
PB Ratio0.00
Price to Fair Value―
Price to FCF0.00
Price to Operating Cash Flow-2.50
PEG Ratio0.00
Income Statement
In the last 12 months, XTL Biopharmaceuticals Sponsored ADR had revenue of 0.00 and earned -6.97M in profits. Earnings per share was -68.00.
Revenue0.00
Gross Profit0.00
Operating Income-1.69M
Pretax Income-759.00K
Net Income-6.97M
EBITDA-752.00K
Earnings Per Share (EPS)-68.00
Cash Flow
In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.
Operating Cash Flow0.00
Free Cash Flow0.00
Free Cash Flow per Share0.00
Dividends & Yields
XTL Biopharmaceuticals Sponsored ADR pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.68
52-Week Price Change-44.67%
50-Day Moving Average2.62
200-Day Moving Average3.35
Relative Strength Index (RSI)55.01
Average Volume (3m)98.27K
Important Dates
XTL Biopharmaceuticals Sponsored ADR upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
XTL Biopharmaceuticals Sponsored ADR as a current ratio of ―, with Debt / Equity ratio of 2.54%
Current Ratio―
Quick Ratio―
Debt to Market Cap―
Net Debt to EBITDA-0.26
Interest Coverage Ratio―
Taxes
In the past 12 months, XTL Biopharmaceuticals Sponsored ADR has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate―
Enterprise Valuation
XTL Biopharmaceuticals Sponsored ADR EV to EBITDA ratio is -0.26, with an EV/FCF ratio of -0.19.
EV to Sales0.00
EV to EBITDA-0.26
EV to Free Cash Flow-0.19
EV to Operating Cash Flow-0.19
Balance Sheet
XTL Biopharmaceuticals Sponsored ADR has $1.14M in cash and marketable securities with $138.00K in debt, giving a net cash position of $1.00M billion.
Cash & Marketable Securities$1.14M
Total Debt$138.00K
Net Cash$1.00M
Net Cash Per Share$0.42
Tangible Book Value Per Share―
Margins
Gross margin is 0.67%, with operating margin of ―, and net profit margin of ―.
Gross Margin0.67%
Operating Margin―
Pretax Margin―
Net Profit Margin―
EBITDA Margin―
EBIT Margin―
Analyst Forecast
The average price target for XTL Biopharmaceuticals Sponsored ADR is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―